Although specific data on COVID-19 are lacking, inflammation can affect cellular transporters such as P-glycoprotein, responsible for imatinib trans-cellular transport (16), that might contribute to increased imatinib exposure. This evidence concerns the gene ABCB1 and COVID-19.